Positive Pre-dose in subsequent period of long acting depot injection [Design Issues]

posted by Compliance – India, 2015-10-15 09:36 (3404 d 09:06 ago) – Posting: # 15564
Views: 6,678

Dear Helmut & Elmaestro,

Thank you very much for sharing your concern. Expiry of reference product is only one year and we are planning to conduct 3-WSABE study due to high variability. Due to this we could not keep long wash out period. however we are taking chance that if pre dose >5 % would be higher then it would not been considered for the BE.

We performed one pilot study and my question comes from that study only. In which we got total 13 subject out of 48 with positive pre dose. Out of 13, 09 subject has shown > 5% pre dose concentration.

Regards,

Compliance

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,667 registered users;
226 visitors (0 registered, 226 guests [including 16 identified bots]).
Forum time: 17:42 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5